Bank of America
ADCT icon

Bank of America’s ADC Therapeutics ADCT Stock Holding History

Bank of America’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Sell
1,288,206
-36,811
-3% -$107K ﹤0.01% 4448
2026
Q1 		$4.97M Buy
1,325,017
+26,433
+2% +$104K ﹤0.01% 3479
2025
Q4 		$4.58M Sell
1,298,584
-62,706
-5% -$254K ﹤0.01% 3463
2025
Q3 		$5.45M Sell
1,361,290
-837,769
-38% -$2.64M ﹤0.01% 3914
2025
Q2 		$5.89M Buy
2,199,059
+397,905
+22% +$837K ﹤0.01% 3724
2025
Q1 		$2.54M Buy
1,801,154
+509,910
+39% +$866K ﹤0.01% 4465
2024
Q4 		$2.57M Sell
1,291,244
-1,206,696
-48% -$3.16M ﹤0.01% 4228
2024
Q3 		$7.87M Buy
2,497,940
+1,281,522
+105% +$4.04M ﹤0.01% 3296
2024
Q2 		$3.84M Buy
1,216,418
+22,571
+2% +$89.7K ﹤0.01% 3861
2024
Q1 		$5.36M Sell
1,193,847
-331,894
-22% -$1.22M ﹤0.01% 3552
2023
Q4 		$2.53M Sell
1,525,741
-8,190
-0.5% -$7.56K ﹤0.01% 4171
2023
Q3 		$1.38M Sell
1,533,931
-132,781
-8% -$177K ﹤0.01% 4578
2023
Q2 		$3.58M Buy
1,666,712
+21,904
+1% +$49.2K ﹤0.01% 3701
2023
Q1 		$3.21M Buy
1,644,808
+40,182
+3% +$148K ﹤0.01% 3949
2022
Q4 		$6.16M Buy
1,604,626
+1,597,765
+23,288% +$6.39M ﹤0.01% 3202
2022
Q3 		$33K Buy
6,861
+519
+8% +$3.76K ﹤0.01% 6826
2022
Q2 		$50K Sell
6,342
-1,267
-17% -$12K ﹤0.01% 6824
2022
Q1 		$112K Sell
7,609
-93,268
-92% -$1.48M ﹤0.01% 6795
2021
Q4 		$2.04M Buy
100,877
+92,621
+1,122% +$2.23M ﹤0.01% 4530
2021
Q3 		$225K Sell
8,256
-1,630
-16% -$41.7K ﹤0.01% 6219
2021
Q2 		$240K Sell
9,886
-3,993
-29% -$92.7K ﹤0.01% 5974
2021
Q1 		$339K Buy
13,879
+11,462
+474% +$332K ﹤0.01% 5663
2020
Q4 		$77K Sell
2,417
-1,500
-38% -$49.2K ﹤0.01% 6112
2020
Q3 		$129K Buy
3,917
+407
+12% +$17.6K ﹤0.01% 5543
2020
Q2 		$164K Buy
+3,510
New +$133K ﹤0.01% 5372

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America's ADCT Position: Q2 2026 in Review

Bank of America reduced its ADC Therapeutics (ADCT) stake by 2.8% in Q2 2026, selling an estimated $107K and leaving 1,288,206 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4448.

Bank of America first reported a position in ADCT in Q2 2020 and has held it in 25 quarters since. The position peaked at $7.87M in Q3 2024. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Bank of America held 1,288,206 shares of ADC Therapeutics worth $1.38M as of Q2 2026.
  • Bank of America sold 36,811 ADC Therapeutics shares in Q2 2026, an estimated $107K.
  • ADC Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #4448 holding.
  • Bank of America first reported a position in ADC Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Bank of America's ADC Therapeutics position peaked at $7.87M in Q3 2024.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.